WOODCLIFF LAKE, N.J., May 22, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has entered into an exclusive U.S. supply and distribution agreement with AstraZeneca to distribute the authorized generic version of AstraZeneca's Atacand ® (candesartan cilexetil). Par has begun shipping 4 mg, 8 mg, 16 mg and 32 mg strengths of candesartan cilexetil tablets. According to IMS Health data, annual U.S. sales of Atacand ® are approximately $113 million.